Leukemia & Lymphoma

June 18, 2019
Published data presented at the ASCO Annual Meeting highlighted the post-approval safety of a biosimilar product for DLBCL.
February 16, 2018
A recent study found that a biosimilar provides improved outcomes without increased risk of toxicity for patients with DLBCL and treatment-induced neutropenia.